Steven B. Heymsfield, MD, Louis J. Aronne, MD, FACP, DABOM, and other panelists will explain insights into the treatment of obesity and overweight from BELIEVE.
Melanie J. Davies, MB, ChB, MD, and other researchers will review data on combination therapy for weight loss using a fixed-dose combination of semaglutide and long-acting amylin analogue cagrilintide.
Panelists including Dimitris Papamargaritis, MCRP, PhD, will discuss emerging therapies targeting the hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin.
Adrian F. Hernandez, MD, MHS, and other experts will outline new developments in heart failure screening, prevention, and therapy related to diabetes.
Panelists including Mindy Lee, MD, PhD, and Yaa Kumah-Crystal, MD, MPH, will review recent advancements in medical technology and artificial intelligence and their potential clinical implications.
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and David Ahn, MD, will assess the impact of non-prescription use of continuous glucose monitors.
Scientific Sessions Meeting Planning Committee Chair Mark A. Atkinson, PhD, highlights high-interest issues to be addressed by experts in the more than 200 sessions offered in Chicago.
Attendees at the Scientific Sessions are invited to ask questions of the diverse faculty and share novel ideas while taking advantage of world-class education.
Join the ADA for the world’s largest diabetes conference, taking place June 20–23 at the McCormick Place Convention Center. Advance registration rates are available through May 8.
A variety of events—including receptions, the Poster Hall, and the Exhibit Hall—will help facilitate networking among attendees throughout the conference.